Stivarga, Regorafenib 40 мг 84 таб. Natco, India
Use of Regorafenib
Metastatic colorectal cancer in patients who have previously received or are not eligible for fluoropyrimidine chemotherapy, anti-vascular endothelial growth factor (VEGF) therapy, and anti-epidermal growth factor receptor (EGFR) therapy in KRAS wild-type; unresectable or metastatic gastrointestinal stromal tumors in patients who have progressed on or are intolerant to imatinib and sunitinib.
Colorectal Cancer. Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy, anti-VEGF therapy, and anti-EGFR therapy in RAS wild-type.
Gastrointestinal stromal tumors. Regorafenib is indicated for the treatment of patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumor who have previously received imatinib and sunitinib.
HCC. Regorafenib is indicated for the treatment of patients with HCC who have previously received sorafenib.
-
Commercial name:stivar
-
Сhemical name:regorafenib
-
Dosage:40 mg
-
Quantity:84
-
Release form:Таб
-
Производитель:Natco, Индия